Cathy Eng, MD, FACP, FASCO, discusses the implications of the fruquintinib approval, as well as other key clinical trial data and regulatory decisions within the colorectal cancer realm in 2023; the importance of early molecular testing in this patient population; and the continued importance of enrolling eligible patients onto clinical trials.
When David Johnson was 11 years old, he was captivated by an eastern screech owl. Today, he's director of the Global Owl Project, which researches the enigmatic bird and works to preserve owl habitat around the world.
According to the findings of an international clinical study published in The Lancet, the selectively targeted medication Fruquintinib resulted in a statistically significant improvement in overall survival and progression-free survival.